Jeffrey M. Leiden

2016 - Vertex Pharmaceuticals

In 2016, Jeffrey M. Leiden earned a total compensation of $17.4M as Chairman, President & CEO at Vertex Pharmaceuticals, a 38% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,246,400
Option Awards$4,060,397
Salary$1,300,000
Stock Awards$9,800,076
Other$12,885
Total$17,419,758

Leiden received $9.8M in stock awards, accounting for 56% of the total pay in 2016.

Leiden also received $2.2M in non-equity incentive plan, $4.1M in option awards, $1.3M in salary and $12.9K in other compensation.

Rankings

In 2016, Jeffrey M. Leiden's compensation ranked 170th out of 14,075 executives tracked by ExecPay. In other words, Leiden earned more than 98.8% of executives.

ClassificationRankingPercentile
All
170
out of 14,075
99th
Division
Manufacturing
53
out of 5,488
99th
Major group
Chemicals And Allied Products
15
out of 1,900
99th
Industry group
Drugs
13
out of 1,543
99th
Industry
Pharmaceutical Preparations
11
out of 1,173
99th
Source: SEC filing on April 28, 2017.

Leiden's colleagues

We found five more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2016.

2016

Michael Parini

Vertex Pharmaceuticals

EVP & Chief Legal and Administrative Officer

2016

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2016

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2016

Amit Sachdev

Vertex Pharmaceuticals

EVP & Chief Regulatory Officer

2016

David Altshuler

Vertex Pharmaceuticals

Chief Scientific Officer

News

You may also like